Cyborg Therapy

Stone, Andy
February 2009
Forbes Asia;2/16/2009, Vol. 5 Issue 2, p74
The article focuses on an experimental machine that can temporarily take over liver function, developed by researchers at the University of Chicago Medical Center, Chicago, Illinois. The goal of the device is to take over enough liver function for a few days or weeks to keep patients alive until doctors find a transplant or the liver regenerates. The device could help patients with acute liver failure due to medication overdose, sudden viral infections or flare-ups of chronic liver disease.


Related Articles

  • Artificial support systems for liver failure. Berk, Paul D.; Scharschmidt, Bruce F.; Martin, James F.; Plotz, Paul H. // Kidney International Supplement;Dec1976, Issue 7, p233 

    Presents a study which focus on artificial support systems for liver failure. Similarities in the role and function of the liver and kidneys; Examination on the necessary characteristics of an artificial device to perform the essential, life-saving functions of the failing liver; Proposal of...

  • VITAGEN ANNOUNCES ENROLLMENT FOR PHASE II TRIAL OF ELAD(r) BIOARTIFICIAL LIVER SUPPORT THERAPY. Stern, Aron // Internet Journal of Dermatology;2002, Vol. 1 Issue 1, p58 

    This article discussesfirst human cell-based bioartificial liver system designed to increase the liver's ability to regenerate and recover. VitaGen Inc. announced that it is currently enrolling patients with fulminant hepatic failure (FHF) in a multicenter Phase II clinical trial as of May 2003....

  • Molecular Absorbent Recirculating System for the Treatment of Acute Liver Failure in Surgical Patients Inderbitzin, Daniel; Muggli, Beat; Ringger, Annette; Beldi, Guido; Gass, Markus; Gloor, Beat; Uehlinger, Dominik; Regli, Bruno; Reichen, Jürg; Candinas, Daniel; Reichen, Jürg // Journal of Gastrointestinal Surgery;Nov2005, Vol. 9 Issue 8, p1155 

    The Molecular Adsorbent Recirculating System (MARS) represents an attractive artificial liver support system for the treatment of liver insufficiency. However, neither indications for MARS treatment (i.e., after extended liver resection) nor criteria for discontinuation of therapy have been...

  • Observation and Nursing Care in Treatment of Hepatic Failure Complications with MARS Artificial Liver. WANG Hong-yue; LANG Lang // Journal of Kunming Medical University / Kunming Yike Daxue Xueba;2014, Vol. 35 Issue 12, p178 

    Objective To discuss the prevention and nursing of MARS artificial liver in the treatment of hepatic failure complications. Method We retrospectively analyzed 162 cases of hepatic failure complications, all of them were treated with MARS artificial liver. Result Complications were found in 148...

  • Clinical Use of a Bioartificial Liver in the Treatment of Acetaminophen-Induced... Detry, Olivier; Arkadopoulos, Nikolaos // American Surgeon;Oct1999, Vol. 65 Issue 10, p934 

    Patients with acetaminophen-induced fulminant hepatic failure (FHF) who meet the King's College Hospital criteria have a high mortality risk (>90%) if they do not undergo liver transplantation. We have developed a treatment strategy for these patients based on the use of an extracorporeal...

  • Predicting survival after living and deceased donor liver transplantation in adult patients with acute liver failure. Jin, Young-Joo; Lim, Young-Suk; Han, Seungbong; Lee, Han; Hwang, Shin; Lee, Sung // Journal of Gastroenterology;Oct2012, Vol. 47 Issue 10, p1115 

    Background: Post-transplant outcomes for acute liver failure (ALF) are unsatisfactory, and there are debates about the most suitable type of graft. Given the critical shortage of donor organs, accurate assessment of post-transplant outcome in ALF patients is crucial to avoid a futile liver...

  • Managing liver failure. Kelly, D.A. // Postgraduate Medical Journal;Nov2002, Vol. 78 Issue 925, p660 

    Focuses on the diagnosis and management of liver failure. Clinical presentation; Neonatal acute liver failure; Hepatitis B; Neonatal hemochromatosis; Tyrosinemia type I; Mitochondrial disorders; Familial hemophagocytic syndrome; Chronic liver failure; Metabolic disorders.

  • The natural history of vertically acquired HCV infection. Tovo, Pier-Angelo // Retrovirology;2008 Supplement 1, Vol. 5, Special section p1 

    The World Health Organization estimates that about 3% of the world population is infected with HCV and 3 million individuals are infected each year. Most of those infected develop chronic liver disease leading, in some cases, to liver failure or hepatocellular carcinoma. Little information is...

  • Iatrogenic EBV-positive lymphoproliferative disorder with features of EBV+ mucocutaneous ulcer: evidence for concomitant TCRγ/IGH rearrangements in the Hodgkin-like neoplastic cells. Di Napoli, Arianna; Giubettini, Maria; Duranti, Enrico; Ferrari, Antonella; Guglielmi, Cesare; Uccini, Stefania; Ruco, Luigi // Virchows Archiv;May2011, Vol. 458 Issue 5, p631 

    The article describes the case of an 81-year-old woman who was diagnosed with iatrogenic Epstein-Barr virus (EBV)-positive lymphoproliferative disorder. She was taken to the Sant' Andrea Hospital of Rome due to abdominal pain. She was subjected to an interventio of left colectomy. After the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics